These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Schwartz TL Psychopharmacol Bull; 2002; 36(2):53-7. PubMed ID: 12397840 [TBL] [Abstract][Full Text] [Related]
4. Vigabatrin and tiagabine might have antipanic properties. Zwanzger P; Rupprecht R J Psychopharmacol; 2004 Sep; 18(3):440. PubMed ID: 15358993 [No Abstract] [Full Text] [Related]
6. Is tiagabine helpful in generalized anxiety disorder? Balon R Ann Clin Psychiatry; 2007; 19(3):197. PubMed ID: 17729022 [No Abstract] [Full Text] [Related]
7. Low-dose tiagabine effectiveness in anxiety disorders. Schaller JL; Thomas J; Rawlings D MedGenMed; 2004 Sep; 6(3):8. PubMed ID: 15520630 [TBL] [Abstract][Full Text] [Related]
8. Tiagabine for the treatment of anxiety. Crane D Depress Anxiety; 2003; 18(1):51-2. PubMed ID: 12900953 [No Abstract] [Full Text] [Related]
9. An open-label study of tiagabine as augmentation therapy for anxiety. Schwartz TL; Azhar N; Husain J; Nihalani N; Simionescu M; Coovert D; Jindal S; Tirmazi S Ann Clin Psychiatry; 2005; 17(3):167-72. PubMed ID: 16433059 [TBL] [Abstract][Full Text] [Related]
10. Comments on article by Mitte and associates: "A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder". Magalhães PV J Clin Psychopharmacol; 2006 Apr; 26(2):220-1; author reply 221. PubMed ID: 16633161 [No Abstract] [Full Text] [Related]
12. A pilot investigation of clinical effects of PM-33, a new anti-anxiety agent. Abuzzahab FS; Kulkarni AS Curr Ther Res Clin Exp; 1974 Nov; 16(11):1181-6. PubMed ID: 4154180 [No Abstract] [Full Text] [Related]
13. Generalized anxiety disorder: between now and DSM-V. Allgulander C Psychiatr Clin North Am; 2009 Sep; 32(3):611-28. PubMed ID: 19716993 [TBL] [Abstract][Full Text] [Related]
14. Tiagabine for social anxiety disorder. Dunlop BW; Papp L; Garlow SJ; Weiss PS; Knight BT; Ninan PT Hum Psychopharmacol; 2007 Jun; 22(4):241-4. PubMed ID: 17476705 [TBL] [Abstract][Full Text] [Related]
15. Potential for adverse events in patients with generalized anxiety disorder. Frackiewicz-Koziol EJ; Sramek JJ; Cutler NR Ann Pharmacother; 1998 Jan; 32(1):132-4. PubMed ID: 9475839 [No Abstract] [Full Text] [Related]
16. For publication: Tiagabine in the discontinuation of long-term benzodiazepine use. Oulis P; Masdrakis VG; Karapoulios E; Karakatsanis NA; Kouzoupis AV; Papadimitriou GN Psychiatry Clin Neurosci; 2009 Feb; 63(1):122. PubMed ID: 19154218 [No Abstract] [Full Text] [Related]
17. A controlled comparison of chlorazepate with oxazepam in neurotic anxiety. Boucek J; Vinar O; Novák A Act Nerv Super (Praha); 1974 Aug; 16(3):239-40. PubMed ID: 4153915 [No Abstract] [Full Text] [Related]
18. On assessing potential efficacy for vortioxetine in generalized anxiety disorder. Baldwin DS; Nutt DJ Eur Neuropsychopharmacol; 2012 Dec; 22(12):841-3. PubMed ID: 22906521 [No Abstract] [Full Text] [Related]
19. Anxiety disorders practice parameters. Krulee DA J Am Acad Child Adolesc Psychiatry; 1994 Jun; 33(5):760-1. PubMed ID: 7914519 [No Abstract] [Full Text] [Related]